Novartis AG (NYSE:NVS) Shares Sold by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC trimmed its position in Novartis AG (NYSE:NVS) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,289 shares of the company’s stock after selling 200 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Novartis were worth $263,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Private Ocean LLC acquired a new position in Novartis in the 1st quarter valued at about $25,000. New Millennium Group LLC acquired a new position in shares of Novartis in the 2nd quarter worth approximately $28,000. Clearstead Trust LLC lifted its holdings in shares of Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after acquiring an additional 114 shares during the last quarter. Lynx Investment Advisory acquired a new position in shares of Novartis in the 2nd quarter worth approximately $29,000. Finally, Industrial Alliance Investment Management Inc. acquired a new position in shares of Novartis in the 2nd quarter worth approximately $30,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Price Performance

Novartis stock opened at $113.80 on Friday. The firm has a market cap of $232.61 billion, a PE ratio of 15.36, a price-to-earnings-growth ratio of 1.66 and a beta of 0.57. Novartis AG has a 52-week low of $92.19 and a 52-week high of $120.92. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. The company’s 50 day moving average is $116.44 and its two-hundred day moving average is $108.42.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on NVS shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a report on Friday, July 19th. The Goldman Sachs Group restated a “neutral” rating and issued a $121.00 price objective (up from $119.00) on shares of Novartis in a report on Thursday, September 5th. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $135.00 to $130.00 in a report on Wednesday, September 11th. Finally, Jefferies Financial Group lowered shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.